Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer

Journal of Clinical Oncology

Volumn 17, Issue 11, 1999, Pages 3412-3417

  Buzdar, Aman U ^a   Singletary, S Eva ^a   Theriault, Richard L ^a   Booser, Daniel J ^a   Valero, Vicente ^a   Ibrahim, Nuhad ^a   Smith, Terry L ^a   Asmar, Lina ^a   Frye, Debra ^a   Manuel, Nikki ^a   Kau, Shu Wan ^a   McNeese, Marsha ^a   Strom, Eric ^a   Hunt, Kelly ^a   Ames, Frederick ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PACLITAXEL; SILVER; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MASTECTOMY; MYALGIA; PARESTHESIA; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; TREATMENT OUTCOME;

EID: 0032751112     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.11.3412     Document Type: Article

References (11)

1. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview or the randomized trials. Lancet 351:1451-1467, 1998
2. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:71-85, 1992
3. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
4. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factors as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
5. Gundoz N, Fisher B, Saffer EA: Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 39:3861-3865, 1979
6. Buzdar AU, Singletary SE, Booser DJ, et al: Combined modality treatment of stage III and inflammatory breast cancer, in Cady B, Bland DI (eds): Surgical Oncology Clinics of America: Management Strategies for the Care of Advanced Primary and Metastatic Breast Cancer. Philadelphia, PA, WB Saunders, 1995, pp 715-734
7. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 2672-2685, 1998
8. Cox DR, Snell EJ: Analysis of Binary Data, London, United Kingdom, Chapman and Hall, 1989, pp 26-52
9. Hortobagyi GN, Buzdar AU, Marcus CE, et al: Immediate and long-term toxicity of adjuvant chemotherapy regimens containing-doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. J Natl Cancer Inst 1:105-109, 1986
10. Henderson IC, Berry D, Demetri G, et al: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 390A)
11. Buzdar AU, Hortobagyi GN, Singletary SE, et al: Impact of FAC-adjuvant therapy on mortality of early breast cancer: Long term results of the M. D. Anderson Cancer Center studies, in Salmon SE (ed): Adjuvant Therapy of Cancer VIII. Philadelphia, PA, Lippincott-Raven, 1997, pp 93-100